2025 연구자 정보 (2 / 654)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Hoffmann, Sarah (Hoffmann, S) |
Charite, Neurosci Clin Res Ctr NCRC, Dept Neurol, Berlin, Germany Charite, Integrated Myasthenia Gravis Ctr, Berlin, Germany Free Univ Berlin, Berlin, Germany Humboldt Univ, Berlin, Germany |
AAV-9916-2021 Hoffmann, Sarah |
0000-0001-9549-2594 Hoffmann, Sarah |
[JCR상위 0.2%] Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised double-blind, placebo-controlled study | SCIE | 0.2 | CLINICAL NEUROLOGY | sramcha4@its.jnj.com | ||
|
Karcher, Keith (Karcher, K) |
Janssen Res & Dev, Stat & Decis Sci, Titusville, NJ 08560 USA |
|
|
[JCR상위 0.2%] Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised double-blind, placebo-controlled study | SCIE | 0.2 | CLINICAL NEUROLOGY | sramcha4@its.jnj.com | ||
|
Kim, Jaekwang (Kim, J) |
Korea Brain Res Inst, Dementia Res Grp, Daegu 41062, South Korea |
|
|
[JCR상위 0.2%] Enhancing the anti-aging potential of the nigrostriatal dopamine system to counteract age-related motor decline | SCIE | 0.2 |
BIOCHEMISTRY & MOLECULAR BIOLOGY CELL BIOLOGY |
srk75@knu.ac.kr | ||
|
Kudo, Masatoshi (Kudo, M) |
Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan |
AAA-9744-2019 Kudo, Masatoshi |
|
[JCR상위 0.2%] Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | bsangro@unav.es | ||
|
Kurland, John F. (Kurland, JF) |
AstraZeneca, Global Med Dev, Gaithersburg, MD USA |
|
|
[JCR상위 0.2%] Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | bsangro@unav.es | ||
|
Lee, Jun-Yeong (Lee, JY) |
Kyungpook Natl Univ, Brain Sci & Engn Inst, Sch Life Sci & Biotechnol, BK21 FOUR KNU Creat Biores Grp, Daegu, South Korea |
|
|
[JCR상위 0.2%] Enhancing the anti-aging potential of the nigrostriatal dopamine system to counteract age-related motor decline | SCIE | 0.2 |
BIOCHEMISTRY & MOLECULAR BIOLOGY CELL BIOLOGY |
srk75@knu.ac.kr | ||
|
Lencioni, Riccardo (Lencioni, R) |
Univ Pisa, Med Sch, Pisa, Italy |
|
|
[JCR상위 0.2%] Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | bsangro@unav.es | ||
|
Lin, Shi-Ming (Lin, SM) |
Chang Gung Mem Hosp, Linkou Med Ctr, Dept Internal Med, Taoyuan, Taiwan |
NPI-5122-2025 Lin, Shiming |
|
[JCR상위 0.2%] Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | bsangro@unav.es | ||
|
Mai, Anh (Mai, A) |
Nhan Dan Gia Dinh Hosp, Gen Surg Dept, Ho Chi Minh City, Vietnam |
|
|
[JCR상위 0.2%] Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | bsangro@unav.es | ||
|
Matos, Marco (Matos, M) |
Pindara Private Hosp, Oncol, Benowa, Qld, Australia |
|
|
[JCR상위 0.2%] Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | bsangro@unav.es | ||
|
Minks, Eduard (Minks, E) |
Masaryk Univ, Dept Neurol, Brno, Czech Republic St Annes Hosp, Brno, Czech Republic |
|
|
[JCR상위 0.2%] Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised double-blind, placebo-controlled study | SCIE | 0.2 | CLINICAL NEUROLOGY | sramcha4@its.jnj.com | ||
|
Nam, Youngpyo (Nam, Y) |
제1저자 | 교신저자 |
Kyungpook Natl Univ, Brain Sci & Engn Inst, Sch Life Sci & Biotechnol, BK21 FOUR KNU Creat Biores Grp, Daegu, South Korea Kyungpook Natl Univ, Brain Sci & Engn Inst, Daegu 41404, South Korea |
|
|
[JCR상위 0.2%] Enhancing the anti-aging potential of the nigrostriatal dopamine system to counteract age-related motor decline [JCR상위 4.1%] Intracerebellar upregulation of Rheb(S16H) ameliorates motor dysfunction in mice with SCA2 |
SCIE | 0.2 |
BIOCHEMISTRY & MOLECULAR BIOLOGY CELL BIOLOGY CHEMISTRY, MULTIDISCIPLINARY PHARMACOLOGY & PHARMACY |
srk75@knu.ac.kr blackpyo2@knu.ac.kr |
|
Nguyen, Quang T. (Nguyen, QT) |
Friendship Hosp, Hanoi, Vietnam |
LYO-9827-2024 Nguyen, Quang |
|
[JCR상위 0.2%] Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | bsangro@unav.es | ||
|
Nowak, Richard J. (Nowak, RJ) |
Yale Univ, Sch Med, Dept Neurol, New Haven, CT USA |
|
|
[JCR상위 0.2%] Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised double-blind, placebo-controlled study | SCIE | 0.2 | CLINICAL NEUROLOGY | sramcha4@its.jnj.com | ||
|
Peron, Jean-Marie (Peron, JM) |
Univ Hosp Purpan, Hepatol Unit, Toulouse, France |
|
|
[JCR상위 0.2%] Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | bsangro@unav.es |
페이지 이동: